Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Sumitomo applies for approval of amrubicin

Dec. 22, 1999

AstraZeneca commences phase II monotherapy trials of ZD-0473

Dec. 21, 1999

Discovery of potent FTase inhibitors with excellent cellular and in vivo activity reported by Abbott

Dec. 21, 1999

Oxford Asymmetry achieves first milestone in collaboration with Ontogeny

Dec. 21, 1999

Phase I clinical trial initiated with OSI's second anticancer agent

Dec. 20, 1999

Genentech's rhuMAb-VEGF will move to phase III study

Dec. 20, 1999

ImClone Systems files IND in U.S. for antiangiogenic agent

Dec. 20, 1999

BMS and Oxigene establish agreement for combretastatin antitumor agents

Dec. 17, 1999

Targeted Genetics commences phase I trial of tgDCC-E1A for ovarian cancer

Dec. 17, 1999

Schwarz to develop Cephalon's prostate cancer drugs in Europe

Dec. 17, 1999

Popular Stories

Today's news in brief
BioWorld
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...
New mechanism of action identified for QC-6352
BioWorld Science
QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...